Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis

This study has been completed.
Information provided by:
Amgen Identifier:
First received: November 17, 2004
Last updated: May 21, 2009
Last verified: May 2009

November 17, 2004
May 21, 2009
October 2004
November 2005   (final data collection date for primary outcome measure)
The proportion of subjects on QM darbepoetin alfa dosing maintained with a mean Hb greater than or equal to 11.0 g/dL and less than or equal to 13.0 g/dL during the evaluation phase [ Time Frame: entire study ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00096915 on Archive Site
  • Hb values over the duration of the study [ Time Frame: entire study ] [ Designated as safety issue: No ]
  • Darbepoetin alfa doses over the duration of the study [ Time Frame: entire study ] [ Designated as safety issue: No ]
  • Frequency and relationship to treatment for adverse events and changes in laboratory parameters and blood pressure [ Time Frame: entire study ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis
A Multicenter, Single-Arm Study Evaluating Once Monthly Darbepoetin Alfa Dosing in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis

The proposed study is designed to test a novel dosing paradigm that would facilitate the treatment of anemia in CKD patients on dialysis. Anemic patients on hemo and peritoneal dialysis who have achieved and maintained target hemoglobin (Hb) on every other week (Q2W) dosing of darbepoetin alfa will have the dosing interval extended to once monthly (QM) dosing.

Not Provided
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Kidney Disease
  • Chronic Kidney Disease
Drug: Darbepoetin Alfa

QM administration for 32 weeks, allowable doses:

15, 20, 30, 40, 50, 60, 80, 100, 150, 200, 300, 400, 500, 600 and 800 mcg

Experimental: darbepoetin alfa
Intervention: Drug: Darbepoetin Alfa
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
November 2005
November 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of chronic kidney disease (CKD) and receiving dialysis for > 3 months before enrollment
  • Clinically stable, in the judgment of the investigator
  • Mean Hb > 11.0 g/dL (110 g/L) to < 13.0 g/dL (130 g/L)
  • Transferrin saturation (Tsat) > 19.5%
  • Serum vitamin B12 and folate levels above the lower limit of the normal range
  • Receiving stable Q2W IV or SC doses of Aranesp® (darbepoetin alfa). A stable dose is defined as less than or equal to 25% change in dose over the 6-week period immediately prior to enrollment and with no missed doses in this period

Exclusion Criteria:

  • Scheduled to receive a kidney transplant
  • Diastolic blood pressure greater than 110 mm Hg or systolic BP greater than 180 mm Hg during screening
  • Acute myocardial ischemia
  • Hospitalization for congestive heart failure, myocardial infarction, deep vein thrombosis, stroke or transient ischemic attack within 12 weeks before enrollment
  • Parathyroid hormone (PTH) level greater than 1500 pg/mL (158.0 pmol/L)
  • Major surgery within 12 weeks before enrollment (excluding vascular access surgery)
  • Currently receiving antibiotic therapy for systemic infection
  • Known positive HIV antibody or positive hepatitis B surface antigen
  • Clinical evidence of current malignancy and/or receiving systemic chemotherapy/radiotherapy with the exception of basal cell or squamous cell carcinoma of the skin and cervical intraepithelial neoplasia
  • Red blood cell (RBC) transfusions within 8 weeks before enrollment
  • Androgen therapy within 8 weeks before enrollment - Systemic hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, hematologic malignancy, myeloma, hemolytic anemia)
  • Any disorder that may impact (in the judgment of the investigator) the ability to give informed consent for participation in this study
  • Pregnant or breast-feeding women
  • All subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial
  • Treatment with an investigational agent or device within 30 days before enrollment or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study
18 Years and older
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Global Development Leader, Amgen Inc.
Not Provided
Study Director: MD Amgen
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP